About
Who We Are
Management Team
Scientific Advisors
Board of Directors
Pipeline & Research
Pipeline
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaborations
Expanded Access Policy
NEWS & MEDIA
Investors
Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance
Careers
Contact Us
Select Page
Corporate Presentation
January 21, 2021
01.20.2021
Corporate Presentation
Download
Search for:
RECENT NEWS ARTICLES
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
BeyondSpring Announces Pricing of Ordinary Shares
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
RECENT MEDIA COVERAGE
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
Developing Triple-Combination Immunotherapies: Lessons Learned From HIV
Meet BeyondSpring: A Fly exclusive interview with CEO Lan Huang
We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.
Ok
Privacy policy
